|Day Low/High||126.10 / 129.29|
|52 Wk Low/High||92.56 / 141.86|
Less than two years later, Alexion is not getting the bang for the mega-bucks it put up for Synageva.
Alexion paid $8.4 billion to acquire Synageva in hopes that its leading rare disease drug would become a billion-dollar product.
Progenics, Alexion and BioCryst were among the biotech stock movers in premarket trading on Thursday.
Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced financial results for the fourth quarter and full year of 2016.
Fed Chair Janet Yellen will give her two-day semiannual monetary policy testimony, while major economic data will drive markets.
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2016 on Thursday, February 16, 2017 before the US...
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C.
This drug maker has risen more than 17% this year. But investors may want to say cautious, unless they are super-aggressive.
The $5.2 billion takeout of Ariad Pharma was the biggest news from the closely followed healthcare conference.
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the Company has submitted marketing applications to the U.
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of...
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the U.
Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at the 35th Annual J.
Every January at 'JPM,' investors take the pulse of the biotech industry for the coming year.
Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) announced today that it has filed with the Securities and Exchange Commission its Form 10-Q for the third quarter ended September 30, 2016.
Adam Feuerstein compiles a list of questions, thoughts, declarations, catalysts and observations about biotech stocks to help investors prepare for the year ahead.
The S&P 500 may be ending 2016 with double-digit gains, but almost a third of the index's individual stocks are actually down this year. Here's how to avoid the laggards.
Start 2017 on the right foot by selling your holdings in these five stocks.
The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Alexion Pharmaceuticals, Inc.
Holzer & Holzer, LLC announces that a class action lawsuit has been filed on behalf of investors in Alexion Pharmaceuticals, Inc.
A look back at the year's worth of Adam Feuerstein's biotech tweets.
The biotech company has been taking a beating lately.
Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today reported results from the PROTECT Study, a Phase 2/3 registration trial of eculizumab (Soliris ®) for the prevention of delayed graft function (DGF) after kidney...
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Alexion Pharmaceuticals, Inc.
Biogen promoted its current Chief Commercial Officer Michel Vounatsos to become the biotech company's next CEO.
Rosen Law Firm, a global investor rights law firm, reminds purchasers of Alexion Pharmaceuticals, Inc.
There was plenty of shame to spread around, but Theranos CEO Elizabeth Holmes' loathsome mix of arrogance, incompetence and duplicity makes her the Worst CEO of 2016.
Former United States Securities and Exchange Commission attorney Willie Briscoe, founder of The Briscoe Law Firm, PLLC, and the securities litigation firm of Powers Taylor LLP announce that a federal class action lawsuit...
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.